TARSONS Tarsons Products Q4 FY25 results (Jan–Mar 2025) and concall
Tarsons Products reported a resilient Q4 FY25, with consolidated revenue growing 7% YoY to INR 113 crores and consolidated EBITDA up 22.4% to INR 37 crores, despite a challenging industry environment. The company saw strong international and domestic revenue growth for FY25. Strategic investments in new facilities (Panchla) are nearing completion, with cell culture production expected by Q4 FY26. While Nerbe's trading model impacts consolidated margins, management is focused on integrating it for European expansion. The company anticipates a broader industry revival in H2 FY26 and expects to r
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 99 | 96 | 113 |
| EBITDA | 25 | 30 | 37 |
| Net profit | 10 | 5 | 10 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
